 |
|
|
|
|
|
|
| Article 1 to 10 out of 23 concerning Abgenix, Inc.
|
-
Scandal in the Pharmaceutical World
(30 Jun 2008)
A large number of the world's largest pharmaceutical companies have illegally used, and profited from, a groundbreaking patent stolen from Nogdan Immunochemicals Ltd., an Israeli biotech company
Nogdan Immunochemicals Ltd.and Mr. Roland Taieb, the exclusive owner of the patent's marketing rights worldwide, announced that many of the world's largest pharmaceutical companies are embroiled in the legal dispute concerning their groundbreaking ...
-
Abgenix Announces Initiation of Phase II Clinical Trial of ABX-EGF in Colorectal Cancer
(28 Dec 2001)
Abgenix, Inc. (Nasdaq: ABGX) announced today the initiation of a Phase II clinical trial of ABX-EGF in patients with colorectal cancer. ABX-EGF is a fully human monoclonal antibody against the epidermal growth factor receptor (EGFr), a receptor ...
-
Abgenix Introduces Enhanced Version of XenoMouse Technology
(05 Dec 2001)
Abgenix, Inc. announced today at the IBC Antibody Engineering Conference in San Diego, Calif., the launch of new versions of XenoMouse® mice that produce fully human monoclonal antibodies that contain both lambda and kappa light chains. Other ...
-
Abgenix Acquires Rights To Novel Cancer Target
(27 Nov 2001)
Abgenix, Inc. (Nasdaq: ABGX) today announced that it has exclusively in-licensed from Duke University Medical Center and Johns Hopkins University a potential new target for the treatment of cancer. This target, known as EGFrvIII, is a member of ...
-
Abgenix Announces CEO Succession Plan
(20 Nov 2001)
Ray Withy to Become CEO in Mid-2000
FREMONT, Calif., November 19, 2001 - Abgenix, Inc. (Nasdaq: ABGX) announced today plans for Raymond Withy, Ph.D., to succeed R. Scott Greer as the company?s chief executive officer effective in mid-2002, and to join the company?s board of ...
-
Abgenix And Agensys Enter Technology License Collaboration To Discover And Develop Human Therapeutic Antibodies Against Cancer
(15 Aug 2001)
Abgenix, Inc. (Nasdaq: ABGX) and Agensys, Inc., a privately-held biotechnology company, announced today a research collaboration, option and license agreement under which the parties will use Abgenix’s human antibody technologies to discover and ...
-
Abgenix Announces Initiation of Phase II Clinical Trial of ABX-EGF in Non-Small Cell Lung Cancer
(01 Aug 2001)
Abgenix, Inc. (Nasdaq: ABGX) announced today the initiation of a Phase II clinical trial of ABX-EGF in patients with non-small cell lung cancer (NSCLC). ABX-EGF is a fully human monoclonal antibody against the epidermal growth factor receptor ...
-
Abgenix Reaches Milestone In Antibody Collaboration With Amgen,
(11 Jul 2001)
Abgenix, Inc. (NASDAQ: ABGX) today announced that Amgen Inc. (Amgen) has advanced into clinical trials a fully human antibody generated with Abgenix’s technology. This milestone triggers an undisclosed payment to Abgenix. "We are pleased with the ...
-
MDS Proteomics And Abgenix Announce Exclusive Agreement To Develop Proteomic-Based Antibody Therapies,
(09 Jul 2001)
MDS Proteomics, a leading proteomics-based drug discovery company, and Abgenix, Inc. (Nasdaq: ABGX), an antibody-based biopharmaceutical company, today announced a collaboration to develop and commercialize antibody drugs. Leveraging MDS ...
-
Abgenix Enters Xenomouse™ Technology Collaboration With Biogen To Generate Fully Human Antibodies
(15 Jun 2001)
Abgenix, Inc. (Nasdaq: ABGX) today announced that it has signed a research collaboration, option and license agreement with Biogen, Inc. under which the parties will use Abgenix’s XenoMouse ™ technology to generate fully human monoclonal ...
|
|
|
|
|
Top